Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1…
Category: GLP-1
Could weight-loss drugs eat the world?
Scientists are finding that anti-obesity medicines can also help many other diseases The gila monster is a poisonous North American lizard…
GLP-1 receptor agonists: Are they friends or foes in colorectal cancer?
Research in mice suggests that blocking, rather than activating the GLP-1 receptor may boost the immune response against colorectal cancer…
Lawsuit could challenge trust in Ozempic and other popular weight loss drugs
The manufacturers of the most popular weight loss drugs are being challengedin court. A federal court in Philadelphia will soon evaluate…
FDA Decision on Zepbound for Sleep Apnea Expected Soon Anticipated FDA Decision on Zepbound by Year-End Eli Lilly has filed…
849-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects—A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study
Background: BGM0504 is an optimized dual GIP and GLP-1 receptor agonist with greater in vitro potency, and similar GLP-1R/GIPR activity…
Merck Eyes Next-Generation Obesity Drugs That Offer Additional Benefits
To break into the lucrative weight loss market, Merck will focus on the development of next-generation anti-obesity medications that offer additional cardiometabolic…
GLP-1 Agonist Prescriptions Rise by Nearly 600% Among Youth From 2020 to 2023
GLP-1 agonists were most frequently prescribed to adolescents and adults by endocrinologists and nurse practitioners, respectively. Dispensing of glucagon-like peptide-1…
Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study
Background In 2021, about 500 million people were estimated to be living with type 2 diabetes throughout the world. The…
GLP-1 agonists linked to reduced dementia risk in type 2 diabetes patients
People with type 2 diabetes who are treated with GLP-1 agonists have a decreased risk of developing dementia, according to…
